EUVIMEDEUVIMED entdecken
Crossref

The ELF1 / IGF2BP2 / FAM111B Cascade Drives Colorectal Cancer Progression and Ferroptosis Resistance

Dian Yin, Lili Cao, Mei Hua, Ying Chen

Clinical and Experimental Pharmacology and Physiology · 2025-12 · 52 (12)

DOI: 10.1111/1440-1681.70090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 10.11.2025. Verfasst von Dian Yin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nantong First People's Hospital, Affiliated Hospital 2 of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ferroptosis, RNA-Binding Proteins, Disease Progression. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic dysregulation plays a critical role in colorectal cancer (CRC) progression. Our study investigated the role of FAM111B in tumorigenic phenotypes and ferroptosis in CRC and the mechanisms by which epigenetic alterations influence FAM111B expression. Bioinformatics analyses revealed FAM111B expression and predicted the association between IGF2BP2 and FAM111B or ELF1. The influence on cell phenotypes was determined by assessing cell proliferation, migration, apoptosis and ferroptosis. Mechanism analyses were performed using luciferase reporter and ChIP assays. Subcutaneous xenografts were used to evaluate the role in vivo. FAM111B, IGF2BP2 and ELF1 were upregulated in CRC tumours and cell lines. FAM111B downregulation inhibited cell proliferation and migration while inducing apoptosis and ferroptosis. IGF2BP2 increased FAM111B expression by stabilising its mRNA, and ELF1 transcriptionally upregulated IGF2BP2. Moreover, ELF1 modulated FAM111B expression through IGF2BP2. ELF1 knockdown suppressed cell proliferation and migration while triggering apoptosis and ferroptosis, which could be abolished by reintroduction of IGF2BP2 or FAM111B. Additionally, ELF1 depletion diminished the in vivo tumorigenicity of HCT116 cells. The ELF1/IGF2BP2/FAM111B cascade drives CRC progression and ferroptosis resistance. Targeting this cascade may provide a therapeutic avenue for CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsFerroptosisRNA-Binding ProteinsDisease ProgressionDNA-Binding ProteinsTranscription FactorsHumansAnimalsMiceCell ProliferationCell MovementGene Expression Regulation, NeoplasticCell Line, TumorMice, NudeHCT116 CellsApoptosis

Stichwörter der Autor:innen

ELF1FAM111BIGF2BP2colorectal cancerepigenetic dysregulationferroptosis

Substanzen

RNA-Binding ProteinsIGF2BP2 protein, humanDNA-Binding ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Oncology, Nantong First People's Hospital, Affiliated Hospital 2 of Nantong University, Nantong, China.

Zitieren

APA

Yin, D., Cao, L., Hua, M., & Chen, Y. (2025). The ELF1 / IGF2BP2 / FAM111B Cascade Drives Colorectal Cancer Progression and Ferroptosis Resistance. Clinical and Experimental Pharmacology and Physiology, 52(12). https://doi.org/10.1111/1440-1681.70090

Vancouver

Yin D, Cao L, Hua M, Chen Y. The ELF1 / IGF2BP2 / FAM111B Cascade Drives Colorectal Cancer Progression and Ferroptosis Resistance. Clinical and Experimental Pharmacology and Physiology. 2025;52(12). doi:10.1111/1440-1681.70090

BibTeX
@article{Yin2025,
  author = {Yin, Dian and Cao, Lili and Hua, Mei and Chen, Ying},
  title = {The ELF1 / IGF2BP2 / FAM111B Cascade Drives Colorectal Cancer Progression and Ferroptosis Resistance},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2025},
  volume = {52},
  number = {12},
  doi = {10.1111/1440-1681.70090}
}
Kostenlos starten →